Bangalore unveils new BT policy

-
In effort to make Karnataka Biotechnology Capital of Asia, the State government, on Wednesday, launched ‘Millennium Biotech policy II’ a successor to Biotech Policy issued of 2001.


Releasing the policy, Principal Secretary IT, BT S&T Ashok Kumar Manoli said the new policy will provide all fiscal incentives and concessions under Karnataka Industry policy 2009-14 to bio technology industry and the R&D centres.

Biotech organisations will get incentives including a subsidy of 50 per cent for setting up effluent treatment plants. The financial incentives includes assistance for patent tracking and patent registration.

According to the new policy biotech will be treated as special industrial consumers and provided with dedicated power lines that are exempt from power cuts. It also assures power connection to biotech companies within 10 days of applications. Bioinforamtics companies that use up to 50 KVA power will be permitted to be established without any local restrictions. The Biotech unit will be exempted from electricity duty of 100 per cent.

The government also express its commitment and importance of creating a start up ecosystem and the government will encourage setting up of venture capital funds for biotech industries called KBIO-Ven fund of Rs 50 crore. Companies with focused area on transgenics, stem cell biology, bio manufacturing and other social relevance will be eligible for funding.

A separate fund of Rs 15-20 crore will be used to issue grants in the range of Rs 10-20 lakh for firms that translate research to commercial projects. The government will also offer tillable agricultural land of 15-20 acres of land and solely for agriculture related bio tech field trials and experiments for a period of 35 years. All R&D labs will be automatically come under the green category, and omitted from pollution control board permission for setting up labs.

The government will set up ten BT finishing school selected by vision group. The government will provide financial support to the schools to set up lab instruments and other technology related gadgets to train students. It will also provide specific infrastructure for the development of biotechnology. This includes promoting of Hi-tech bio tech park in the state. A 106 acre Biotech park Bangalore Helix is coming up in Electronic City. A Bio-IT park in a 100 acre plant in Ramanagaram is also planned.


Click here for the Policy. Note: File size - 18 mb

Launch of Millenium BT Policy



XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.









Comments

Post a Comment

Popular posts from this blog

Sequence Analysis is still sexy:Dual Descriptor Method for Biological Sequence Analysis

-
The emergence of “Systems Biology” in recent years highlights the systematic viewpoint of bio-system modeling. Building on such a background, Dual Descriptor Method, a generic methodology for biological sequence analysis is proposed. From a systematic perspective, Dual Descriptor is defined as a two element set of Composition Weight Map and Position Weight Function which aim at reflecting the composition and permutation information of a sequence. An alternate training algorithm is provided to get an optimum description of the building patterns of the sequences. In this paper , dual descriptor method has been applied to the analysis of two typical problems of molecular biology: gene identification and the prediction of protein function. Satisfactory and insightful results are achieved. Owing to the generality of this methodology, dual descriptor method has wide application perspective for many problems of pattern recognition, especially those involved in “Systems Biology”. Be a part of
Read more

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

-
Abbott May 21 announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion , plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio. "This strategic action will advance Abbott into the leading market position in India , one of the world's most attractive and rapidly growing markets," said Miles D. White , chairman and chief executive officer, Abbott. &quo
Read more

List of Cheminformatics Companies & Institutions

-
Accelrys ACD/Labs (Advanced Chemistry Development, Inc.) Afferent Systems Inc. Agilent Technologies Aureus Pharma Barnard Chemical Information Ltd. (John Barnard and Geoff Downs) SEE: digital chemistry Bio-Rad Laboratories BioReason BioSolveIT BlueObelisk.org Bruker Daltonics Inc. Cambridge Crystallographic Data Centre CambridgeSoft Corporation CARB Center for Advanced Research in Biotechnology (NIST/University of Maryland) Cengent Therapeutics (Genes to Leads). Acquired by Inncardio, Inc. Center for Molecular Modeling (NIH) Centre for Molecular and Biomolecular Informatics CMBI (formerly: CAOS/CAMM: Dutch National Center for Computer-Assisted Chemistry and Molecular Modelling) Cerep ChemAxon ChemDiv, Inc. (Chemical Diversity) Chemical Abstracts Service Chemical Computing Group, Inc. Chemical Simulations Group ChemInnovation Software ChemNavigator ChemSW (Chemistry Software for Windows, formerly: WindowChem) Chenomx Inc. CIS Chemical Information System CombiChem.net CompuChem C
Read more